PROVECTUS BIOPHARMACEUTICALS, INC. 8-K

What Happened
Provectus Biopharmaceuticals, Inc. filed an 8-K reporting that on January 30, 2026 it adopted amendments to the Certificates of Designation for its Series D and Series D‑1 Convertible Preferred Stock. The company’s board of directors and a special committee of independent directors approved the amendments, which move the automatic conversion date for both Series D and Series D‑1 from June 20, 2026 to December 31, 2028.

Key Details

• The Amendments were filed with the Delaware Secretary of State on January 30, 2026.
• Previous Automatic Conversion Date: June 20, 2026. New Automatic Conversion Date: December 31, 2028.
• Affects: Series D and Series D‑1 Convertible Preferred Stock (both par value $0.001 per share).
• The full text of each Certificate of Amendment is included as exhibits to the 8‑K.

Why It Matters
For investors, this change delays the automatic conversion of these preferred shares into common stock, meaning the preferred equity will remain outstanding longer than previously scheduled. That can affect the timing of potential dilution to common shareholders and the company’s capital structure until conversion occurs. The filing is procedural—approved by the board and an independent special committee—and does not provide reasons beyond the amendment itself.